期刊文献+

hTERT核心启动子驱动的条件复制型腺病毒载体的构建及鉴定 被引量:1

Construction and verification of a novel CRAd driven by hTERT promoter
下载PDF
导出
摘要 目的构建并鉴定一种新型人端粒酶逆转录酶(hTERT)启动子驱动的条件复制型腺病毒载体。方法采用PCR的方法克隆腺病毒E1区基因(E1A,E1B55K)、E1B的启动子(E1Bp)以及人端粒酶逆转录酶亚基启动子(hTERTp),以及2个目的基因:人GM-CSF和GFP(GreenFluorescenceProtein,GFP)。采用一系列分子生物学方法构建pShuttle-GFPSV55K穿梭质粒,应用此穿梭质粒与AdEasy-1腺病毒DNA在BJ5183细菌内重组得到重组腺病毒质粒,将其转染293细胞获得Ad-GFPSV55K重组腺病毒。PCR法鉴定重组腺病毒,噬斑形成实验测病毒滴度。结果经过酶切鉴定成功地构建了分别携带GM-CSF基因和GFP报告基因的腺病毒载体,病毒滴度为7×1010pfu/ml。结论成功获得由hTERT启动子驱动的条件复制型腺病毒载体,为肿瘤的基因治疗打下良好的基础。 Objective To construct a novel CRAd vectors driven by hTERT promoter and to establish the foundation for cancer gene therapy. Methods The hTERT promoter as E1A and E1Bp gene were amplified by PCR;the GFP gene and GM-CSF were also amplified by PCR, and the products were subcloned into Teasy plasmid in certain order to generate pSh-GFP-SV55K plasmid. A recombinant adenoviral genomic DNA was obtained by homologous recombinant in E. coli BJ5183 cells pretransformed with the pAdeasy-1 plasmid (BJ5183-AD-1 cells) ; the recombinant adenovirus Ad-GFP-SV55K was gained after transfecting 293 cell line with the genomic DNA using LepofectAMINE method ; PCR was used to identify the recombinant Ad, and the titer of virus was determined by plaque assay in the 293 cells. Results The structure of the adenovirus vectors carrying GM-CSF gene and GFP gene was identified by restriction enzyme analysis. The titer of the virus was 7 × 10^10 pfu/ml. Conclusion A novel recombinant adenovirus vector driven by hTERT promoter is made successfully, and the newly constructed adenovirus is useful for cancer gene therapy.
出处 《安徽医科大学学报》 CAS 北大核心 2006年第1期19-22,共4页 Acta Universitatis Medicinalis Anhui
基金 国家973课题(编号:2004CB518801) 国家自然科学基金资助(编号:30470735) 安徽省人才开发基金资助(编号:2002Z035)
关键词 末端转移酶/遗传学 腺病毒科 发光蛋白质类/遗传学 telomerase/genetics adenoviridae luminescent proteins/genetics
  • 相关文献

参考文献11

  • 1Majumdan N S.Hughes DE,Lichtsteimer SP,et al.The telomerase reverse transcriptase promoter drives effiencious tumor suicide gene therapy while preventing hepatoloxicity encountered with constitutive promoters[J]. Gene Ther, 2001,8(7) :568 -78.
  • 2Jacob D, Bahra M, Schuma cher D, et al. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter[J]. Anticancer Res,2004,24(5A) :3075 -9.
  • 3Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase ( hTER and hTERT ) for selective killing of cancer cells[J]. Mol Ther, 2000,2(6) :539 -44.
  • 4Kim N W, Piatyszek M A, Prowse K R, et al. Specific association of human telomerase activity with immortal cells and cancer [J].Science (Wash. DC), 1994,266(5193) : 2011 -5.
  • 5Shay J W, Wright W E. Telomerase activity in human cancer[J].Curr Opin Onco1,1996, 8( 1 ) : 66 -71.
  • 6Hemminiki A, Alvarez R D. Adenovirus in oncology: a vilable option [ J ] ? BioDrugs,2002,16 ( 2 ) :77 - 87.
  • 7Todo T,Rabkin S D, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated,replication-competent hepes simplex virus [ J ]. Hum Gene Ther,1999,10 (17) :2741 - 55.
  • 8Heise C, Hermiston T, Johnson T, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumor efficacy[J]. Nat Med,2000,6(12) :1134 -9.
  • 9Takahashi M. EIB-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replictionin AFP-producing hepatocellular carcinomar and eradication of established tumor[J]. Mol Ther, 2002,5(Sptl) :627 -34.
  • 10Yu D C ,Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer specific adenovirus, and paclitaxel and docetaxel[J]. Cancer Res, 2001,61(2) :517 -25.

同被引文献9

  • 1陈艳,叶大风,谢幸.血清CA125测定在上皮性卵巢癌病情监测中的作用[J].国外医学(计划生育分册),2005,24(2):90-94. 被引量:6
  • 2徐怡,黄艳春,雷君,吉军.血清CA125检测对恶性肿瘤的临床诊断价值[J].新疆医科大学学报,2007,30(1):69-71. 被引量:7
  • 3O′Brien T J,Beard J B,Underwood L J,et al.The CA 125 gene:an extracellular superstructure dominatedby repeat sequences[J].Tumour Biol,2001,(22):348-66.
  • 4O′Brien T J,Beard J B,Underwood L J,et al.The CA 125gene:a newly discovered extension of the glycosylated Nterminaldomain doubles the size of this extracellular superstructure[J].Tumour Biol,2002,(23):154-69.
  • 5Kui Wong N,Easton R L,Panico M,et al.Characterizationof the oligosaccharides associated with the humanovarian tumor marker CA125[J].Biol Chem,2003,(278):28619-34.
  • 6Brien O,Timothy.Monoclonal antibodies which identify the glycoprotein carrying the CA125 epitope[J].United States,1991,(165):1857-64.
  • 7Rustin G J,Marples M,Nelstrop A E,et al.Use of CA125 to define progression of ovarian cancer in patients with persist-ently elevated levels[J].Clin Oncol,2001,(19):4054-7.
  • 8Jennifer A A,Jennifer B,Masanori O,et al.Mesothelin-MUC16 binding is a high affinity,N-glycan dependentinteraction that facilitates peritoneal metastasis of ovaria tumors[J].Molecular Cancer,2006,5(1):51.
  • 9Yin B W,Dnistrian A,Lioyd K O.Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene[J].Cancer,2002,(98):737-40.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部